CRL Earnings

CRL reported its earnings on 2026-05-07, showcasing a revenue of 995.83M against an estimate of 971.06M, resulting in a 2.55% surprise. The EPS was 2.06, surpassing the expected 1.96 by 5.1%. The stock experienced a -0.03% price change on the earnings day and a -7.18% change over the next five days, reflecting market reactions to the results.

Following CRL's earnings announcement on 2026-05-07, the stock price moved by -0.03% on the day of the release. Over the subsequent five days, it saw a -7.18% change. Historically, CRL's stock price tends to shift by an average of 1.81% in the 10 days leading up to earnings and 1.5% in the 10 days following, providing insight into potential market.

For 2026/Q2, analysts estimate CRL's annual revenue to reach 1.03B, while the EPS is projected at 2.84. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between CRL's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, CRL's stock price typically moves by 1.81% in the 10 days before its earnings and 1.5% in the 10 days after. For the upcoming 2026/Q2 earnings, analysts expect an EPS of 2.84 and revenue of 1.03B.

The earnings call summary reveals solid financial performance, optimistic guidance, and strategic initiatives that indicate potential growth. The Q&A section highlights positive trends such as increased proposal volumes, AI's potential in drug discovery, and improving margins. Although there are some uncertainties, like the sluggish demand from smaller biotechs, the overall sentiment is positive due to strong financial metrics, optimistic guidance, and strategic focus on M&A and capital allocation. Despite the lack of market cap data, these factors suggest a likely positive stock price movement in the short term.